Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

There are several endogenous molecules that can trigger migraine attacks when administered to humans.

Notably, calcitonin gene-related peptide (CGRP) has been identified as a key player in a signalling cascade involved in migraine attacks, acting through the second messenger cyclic adenosine monophosphate (cAMP) in various cells, including intracranial vascular smooth muscle cells.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

The subject headings attached to it are Receptors, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide, Cilostazol, Migraine Disorders, Second Messenger Systems and Cyclic AMP.

The authors tagged it with the keywords PACAP, cranial arteries, migraine model and vasodilation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The publication is from 2023 (Brain : a journal of neurology), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.